Health Economics›Non-small cell lung cancer squamous›Advanced or metastatic disease second-line

Advanced or metastatic disease second-line

Non-small cell lung cancer squamous · 3 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Afatinib monotherapy Variant #01	—	R 34 727	28d	2.4 mo	7.8 mo	3	R 104 182 PFS proxy	2
Docetaxel monotherapy N/A - secondary systemic drug	—	R 243	28d	—	7.1 mo	—	—	2
Sintilimab monotherapy Variant #01 Partial	—	—	14d	—	11.8 mo	—	—	1

3 of 3 regimens shown